| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |